Highlights of the 2nd International Symposium on Tribbles and Diseases: Tribbles Tremble in Therapeutics for Immunity, Metabolism, Fundamental Cell Biology and Cancer
View/ Open
Date
2019-03Author
Cui, Bing
Eyers, Patrick A.
Dobens, Leonard L.
Tan, Nguan Soon
Mace, Peter D.
Link, Wolfgang A.
Kiss Toth, Endre
Keeshan, Karen
Nakamura, Takuro
Pear, Warren S.
Feseha, Yodit
Johnston, Jessica
Scheideler, Marcel
llyas, Zabran
Bauer, Robert C.
Erusalimsky, Jorge D.
Grzesik, Dominika
Salamanca Viloria, Juan
Lv, Xiaoxi
Jin, Yishi
Li, Ke
Velasco, Guillermo
Shang, Shuang
Lizcano de Vega, José Miguel
Zhang, Xiaowei
Zhou, Jichao
Yu, Jiaojiao
Hua, Fang
Wang, Feng
Liu, Shanshan
Yu, Jinmei
Hu, Zhuowei
Metadata
Show full item record
Acta Pharmaceutica Sinica B 9(2) : 443-454 (2019)
Abstract
The Tribbles (TRIB) family of pseudokinase proteins has been shown to play key roles in cell cycle, metabolic diseases, chronic inflammatory disease, and cancer development. A better understanding of the mechanisms of TRIB pseudokinases could provide new insights for disease development and help promote TRIB proteins as novel therapeutic targets for drug discovery. At the 2nd International Symposium on Tribbles and Diseases held on May 7-9, 2018 in Beijing, China, a group of leading Tribbles scientists reported their findings and ongoing studies about the effects of the different TRIB proteins in the areas of immunity, metabolism, fundamental cell biology and cancer. Here, we summarize important and insightful overviews from 4 keynote lectures, 13 plenary lectures and 8 short talks that took place during this meeting. These findings may offer new insights for the understanding of the roles of TRIB pseudokinases in the development of various diseases. (C) 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.